Family Medicine Doctors in Mccleary, WA Accepting Medicare
2 Family Medicine doctors found. Showing 1 - 2
 Dr. Michael Lee Thorpe, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 322 S Birch St, Mccleary, WA 98557 Phone: 360-495-3500 Fax: 360-495-4423 |
Mark Henry Genich, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 322 S Birch St, Mccleary, WA 98557 Phone: 360-495-3500 Fax: 360-495-4423 |
News Archive
Apixaban superior to enoxaparin in reducing venous thromboembolism in total knee replacement surgery patients
Apixaban, an oral anticoagulant being developed by Bristol-Myers Squibb Company and Pfizer Inc., was statistically superior to 40 mg once daily enoxaparin in reducing the incidence of venous thromboembolism in patients undergoing elective total knee replacement surgery, according to the ADVANCE-2 study results published today in The Lancet. The study results also showed numerically lower rates of major and clinically relevant non-major bleeding in patients treated with apixaban compared with those treated with enoxaparin.
JHP Pharmaceuticals completes successful GMP/Pre Approval Audit by FDA CDER
JHP Pharmaceuticals' sterile manufacturing site based in Rochester, Michigan completed a successful GMP (Good Manufacturing Practices)/Pre Approval Audit by the U.S. Food and Drug Administration (FDA) drug division (CDER).
Aggression influences new nerve cell production in the brain
A group of neurobiologists from Russia and the USA, including Dmitry Smagin, Tatyana Michurina, and Grigori Enikolopov from Moscow Institute of Physics and Technology, have proven experimentally that aggression has an influence on the production of new nerve cells in the brain.
Genentech announces positive results from Phase II study of T-DM1
Genentech, Inc., a wholly owned member of the Roche Group, today announced positive results from a Phase II study of trastuzumab-DM1 (T-DM1). As assessed by independent review, T-DM1 shrank the tumors (also known as objective response) in 33 percent of women with advanced (metastatic) HER2-positive breast cancer that had worsened following previous treatment.
› Verified 9 days ago